# Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)

> **NCT03780959** · PHASE2,PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 69 (actual)

## Conditions studied

- Juvenile Rheumatoid Arthritis

## Interventions

- **DRUG:** Etanercept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03780959
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-05-01
- **Primary completion:** 1998-07-08
- **Final completion:** 1998-07-08
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2019-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03780959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03780959, "Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03780959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*